GTS Securities’s Barinthus Biotherapeutics BRNS Stock Holding History

GTS Securities’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-73,210	Closed	-$41.9K	–	1392
2026 Q1	$41.9K	Buy	+73,210	New	+$48.2K	﹤0.01%	1441

Other funds holding BRNS

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return

GLR Partners Columbia, Maryland $215M AUM

DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

JHU

Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

GTS Securities's BRNS Position: Q2 2026 in Review

GTS Securities sold out of Barinthus Biotherapeutics (BRNS) in Q2 2026, closing a stake of 73,210 shares — an estimated $41.9K sold.

GTS Securities first reported a position in BRNS in Q1 2026 and held it in 1 quarter. The position peaked at $41.9K in Q1 2026. 15 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

GTS Securities reported no remaining Barinthus Biotherapeutics position as of Q2 2026 after selling out during the quarter.
GTS Securities sold 73,210 Barinthus Biotherapeutics shares in Q2 2026, an estimated $41.9K.
GTS Securities first reported a position in Barinthus Biotherapeutics in Q1 2026 and held it in 1 quarter.
GTS Securities's Barinthus Biotherapeutics position peaked at $41.9K in Q1 2026.
15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.